How safe is GlaxoSmithKline plc’s dividend?

Are dividends built to endure at GlaxoSmithKline plc (LON: GSK), or is trouble ahead?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) is one of the largest firms listed in the FTSE 100 by market capitalisation and as such, is bound to attract the attention of dividend-seeking investors.

One market aphorism has it that income strategies tend to beat growth strategies. So it could pay to seek out at least some reliable dividend generators when building a portfolio of shares.

At first glance, GlaxoSmithKline seems attractive. Today’s share price around 1,644p throws up a forward dividend yield of almost 4.9% for 2017.

A defensive sector with issues

Big firms such as GlaxoSmithKline in the pharmaceuticals sector tend to have business models similar to consumer goods businesses in other sectors. Whenever a company comes up with a product that customers buy, use up, and buy again repeatedly, cash generation can be reliable and predictable for the business. In the case of GlaxoSmithKline, customers rarely forego their medicines so, in theory, the firm enjoys the defensive, cash-generating qualities that we should be looking for in a dividend investment.

By now, you will probably already be familiar with the so-called patent cliff faced by big pharmaceuticals firms over recent years. Several of GlaxoSmithKline’s big-selling and profitable lines all came to the end of their patent protection periods at around the same time, opening the way for generic competition to swoop into the market with cut-price offerings. The effect on GlaxoSmithKline’s profits was significant. Earnings per share fell for the last four years, first by 2% then by 3%, 12% and a massive 21%.

The company fought the patent-expiry issue by bearing down on costs and working hard to develop new potential blockbuster drugs from its research and development pipeline. The measures are taking effect, and City analysts predict a return to earnings growth during 2016, with EPS up around 27%. That’s encouraging. 

Keeping the faith

Consumer goods firms in other sectors, such as Unilever, don’t rely on patent protection so much as on the strength of their brands to attract customers. So even though profits might be lower than previously enjoyed, I think it’s reasonable to assume that GlaxoSmithKline can still be a reliable cash generator and a solvent business even when challenged by competition. I wonder if such thinking is what kept well-known fund manager Neil Woodford invested in GlaxoSmithKline when the shares were down near 1,000p during 2009?

I looked at the shares myself back then but didn’t have Neil Woodford’s insight. I wish I had because a 64% capital gain plus generous dividend income over the last seven years isn’t to be sniffed at. All that was achieved during a period of crisis and falling earnings, remember, so what might happen when things are going well for the business? Such can be the power of good dividend-paying defensives.   

The dividend payout rose a little each year until 2015 when the directors held it at 2014’s level of 80p per share. By then, adjusted earnings per share dipped slightly below the level of the dividend, so it was prudent not to raise the payout further. In recent guidance, the firm told us it intends to maintain the dividend at 80p per share for 2016 and 2017 too. As cash flow and earnings rebuild — and the outlook is positive — I think right now could be a good time to add GlaxoSmithKline to a portfolio for income.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »